XTANDI® plus Leuprolide Reduced the Risk of Metastasis by 58% in Non-Metastatic Hormone-Sensitive Prostate Cancer versus Placebo plus Leuprolide
LifeProNow
APRIL 30, 2023
Optimize management of cardiovascular risk factors, such as hypertension, diabetes, or dyslipidemia. Discontinuations due to adverse events (AEs) were reported for 16% of XTANDI-treated patients. Grade 3-4 ischemic events occurred in 1.4% of patients on XTANDI versus 0.7% on placebo. events led to death in 0.4% on placebo.
Let's personalize your content